Krilogy Financial LLC Invests $577,000 in Elevance Health, Inc. $ELV

Krilogy Financial LLC acquired a new stake in shares of Elevance Health, Inc. (NYSE:ELV) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,814 shares of the company’s stock, valued at approximately $577,000.

Several other large investors have also recently added to or reduced their stakes in ELV. Axxcess Wealth Management LLC lifted its holdings in shares of Elevance Health by 27.0% during the 2nd quarter. Axxcess Wealth Management LLC now owns 1,436 shares of the company’s stock valued at $558,000 after buying an additional 305 shares during the last quarter. Mutual Advisors LLC raised its position in Elevance Health by 17.0% during the second quarter. Mutual Advisors LLC now owns 2,370 shares of the company’s stock valued at $922,000 after acquiring an additional 345 shares in the last quarter. Arista Wealth Management LLC acquired a new stake in Elevance Health in the second quarter valued at approximately $537,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Elevance Health in the second quarter worth approximately $15,714,000. Finally, International Assets Investment Management LLC acquired a new position in shares of Elevance Health during the 2nd quarter worth $38,938,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ELV. Wells Fargo & Company reduced their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Sanford C. Bernstein reduced their price target on Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Guggenheim dropped their target price on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. Morgan Stanley cut their target price on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Finally, Robert W. Baird raised their price target on Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Twelve equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Stock Up 3.1%

NYSE ELV opened at $346.49 on Friday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The stock has a market cap of $76.47 billion, a PE ratio of 13.79, a PEG ratio of 1.93 and a beta of 0.50. The firm has a 50-day simple moving average of $352.22 and a 200 day simple moving average of $332.03. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the company earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, research analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is currently 27.23%.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.